Претрага

Резултати

Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990-2021: findings from the Global Burden of Disease Study 2021 [2023]

Gardner, William M.; ...; Ilić, Irena M. ; ...; (broj koautora 558)

Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3trial [2023]

Dimopoulos, Meletios Athanasios; ...; Bila, Jelena S ; ...; (broj, koautora 21)

Antithrombin deficiency in pregnancy-the unresolved issues [2020]

Kovac, Mirjana K

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial [2017]

Davies, Andrew; Merli, Francesco; Mihaljevic, Biljana S ; Mercadal, Santiago; Siritanaratkul, Noppadol; Solal-Celigny, Philippe; Boehnke, Axel; Berge, Claude; Genevray, Magali; Zharkov, Artem;

Dixon, Mark; Brewster, Michael; Barrett, Martin; MacDonald, David;

Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990-2021: findings from the Global Burden of Disease Study 2021 [2023]

Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3trial [2023]

Antithrombin deficiency in pregnancy-the unresolved issues [2020]

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial [2017]

Филтери